Aptevo Therapeutics Inc.

APVO Healthcare Biotechnology

Aptevo Therapeutics Inc.’s revenue for fiscal 2022 (year ended December 2022) was $3.1 million. In the quarter to June 2026, EPS grew 96.5% and free cash flow grew 23.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.62 0.08 −4.71%
Market cap
$3.1M
P/E
0.0×
Fwd P/E
−0.5×
Dividend yield
—
F-score
4/9
Altman Z
256174.47
Beneish M
3.69
Dividend safety
n/a

A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.

Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Net Income
(26.41) (26.26) (25.97) (26.47)

+8 more TTM periods

Operating Cash Flow
(25.34) (26.98) (25.59) (26.11)
Investing cash flow
— — — —
Financing cash flow
25.73 39.37 45.22 44.33
Ending Cash
22.01 34.01 21.62 22.02

Show all line items

In millions of $ except per-share values · columns are period end dates